false
0000319016
0000319016
2023-08-14
2023-08-14
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 15, 2023 (August 14, 2023)
FUSE MEDICAL, INC.
(Exact name of Registrant as Specified in Its Charter)
|
Delaware
|
000-10093
|
59-1224913
|
|
(State or Other Jurisdiction
of Incorporation)
|
(Commission File Number) |
(IRS Employer
Identification No.)
|
|
1565 North Central Expressway
Suite 220 Richardson, Texas
|
|
75080
|
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrant’s Telephone Number, Including Area Code: (469) 862-3030
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange on which registered
|
|
Common Stock
|
|
FZMD
|
|
OTCPink
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
The information in Item 2.02 of this report (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing.
On August 15, 2023, Fuse Medical, Inc. (the “Company”) issued a press release reporting the financial results of the Company for the second quarter ending June 30, 2023. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit
Number
|
|
Description
|
|
99.1*
|
|
|
| 104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
* Filed herewith.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
Fuse Medical, Inc.
|
|
|
|
|
|
Date: August 15, 2023
|
By:
|
/s/ Lawrence Yellin
|
|
|
|
Lawrence Yellin
|
|
|
|
Chief Financial Officer and Director
|
Exhibit 99.1
Contact:
Fuse Medical, Inc.
Attention: Lawrence Yellin, CFO
1565 North Central Expressway, Suite 220
Richardson, Texas 75080
Office (469) 862-3030
Facsimile (469) 862-3035
info@Fusemedical.com
FUSE MEDICAL, INC. ANNOUNCES SECOND QUARTER 2023 FINANCIAL RESULTS
August 15, 2023
RICHARDSON, TX, [DATE] /Businesswire/ --On August 14, 2023, Fuse Medical, Inc. (OTCPINK: FZMD) (“Fuse” or the “Company”) an emerging manufacturer and distributor of innovative medical devices for the orthopedic and spine marketplace, filed its quarterly report on Form 10-Q for the quarter ended June 30, 2023 with the Securities and Exchange Commission (“SEC”).
Second Quarter 2023 Financial Highlights
| |
●
|
Net revenues for the quarter ended June 30, 2023 were $5.0 million, compared to $4.7 million for the quarter ended June 30, 2022 which was an increase of approximately 7%.
|
| |
●
|
For the quarter ended June 30, 2023, gross profit was $3.5 million, or 69% of revenues, compared to $2.6 million, or 57% of revenues, for the quarter ended June 30, 2022, which was an increase of 31%.
|
| |
●
|
Selling, general, administrative, and other expenses (“SG&A”) for the quarter ended June 30, 2023 was approximately $1.6 million compared to $1.4 million for the quarter ended June 30, 2022.
|
| |
●
|
Commissions expense for the quarter ended June 30, 2023 decreased to $1.4 million from $1.5 million for the quarter ended June 30, 2022, a decrease of approximately $14,702.
|
| |
●
|
For the quarter ended June 30, 2023, net income was $307,588 compared to a loss of $322,936 for the quarter ended June 30, 2022, reflecting an increase in net income of $630,524.
|
| |
●
|
For the quarter ended June 30, 2023, EBITDA was $401,574 compared to an EBITDA loss of $246,834 for the quarter ended June 30, 2022, reflecting an increase in EBITDA income of $648,408.
|
Christopher C. Reeg, Chief Executive Officer of Fuse Medical, commented, “We are pleased with our second quarter performance, as highlighted by a 7% increase in revenue, a 31% increase in gross profit, and a $648,408 increase in EBITDA over the prior-year period. Our implementation and achievement of strategic initiatives, which includes increasing our portfolio of Fuse branded and manufactured products, is reflected in our second quarter results.”
Mr. Reeg further added, “Our growth for the remainder of 2023, and into 2024 is focused on continued design and development of unique medical devices for commercialization, new product launches in the orthopedics and spine marketplace, and expansion of our national distribution footprint. We expect the execution of these strategic initiatives to drive growth in the near term, while increasing our visibility as an emerging manufacturer of relevant medical devices.”
About Fuse Medical, Inc.
Fuse is an emerging manufacturer and distributor of innovative medical devices for the orthopedic and spine marketplace. We provide a comprehensive portfolio of products in the orthopedic total joints, sports medicine, trauma, foot and ankle space, as well as, degenerative and deformity spine, osteobiologics, wound care, and regenerative products. For more information about the Company, or if you’re interested in becoming a distributor of any Fuse’s products, please contact us at info@fusemedical.com or visit: www.fusemedical.com.
Forward Looking Statements
Certain statements in this press release, constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend,” or similar expressions or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based only on information available to the Company as of the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including, without limitation, those set forth in the Company’s filings with the Securities and Exchange Commission; the failure of the Company to close the transaction; and integration issues with the consolidated company. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events, or otherwise, except as required by law.
Note Regarding Use of Non-GAAP Financial Measurements:
The financial data contained in this press release includes certain non-GAAP financial measures as defined by the Securities and Exchange Commission ("SEC"), including "EBITDA". The Company is presenting EBITDA because it believes that it provides useful information to investors about Fuse, its business and its financial condition. The Company defines EBITDA as net income or loss from continuing operations before the effects of interest expense, taxes, depreciation and amortization. The Company believes EBITDA is useful to investors because it is one of the measures used by the Company's Board of Directors and management to evaluate its business, including in internal management reporting, budgeting and forecasting processes, in comparing operating results across the business, as an internal profitability measure, as a component in evaluating the ability and the desirability of making capital expenditures and significant acquisitions, and as an element in determining executive compensation.
However, EBITDA is not a measure of financial performance under generally accepted accounting principles in the United States of America ("GAAP"), and the items excluded from EBITDA are significant components in understanding and assessing financial performance. Therefore, EBITDA should not be considered a substitute for net income (loss) or cash flows from operating, investing, or financing activities. Because EBITDA is calculated before recurring cash charges including interest expense and taxes, and is not adjusted for capital expenditures or other recurring cash requirements of the business, it should not be considered as a measure of discretionary cash available to invest in the growth of the business. There are a number of material limitations to the use of EBITDA as an analytical tool, including the following:
| |
●
|
EBITDA does not reflect the Company's interest expense;
|
| |
●
|
EBITDA does not reflect the Company's tax expense or the cash requirements to pay its taxes; and
|
| |
●
|
Although depreciation and amortization are non-cash expenses in the period recorded, the assets being depreciated and amortized may have to be replaced in the future, and EBITDA does not reflect the cash requirements for such replacement.
|
The Company compensates for these limitations by relying primarily on its GAAP financial measures and by using EBITDA only as supplemental information. The Company believes that consideration of EBITDA, together with a careful review of its GAAP financial measures, is the most informed method of analyzing Fuse Medical, Inc.
The Company reconciles EBITDA to net income, and that reconciliation is set forth below. Because EBITDA is not a measurement determined in accordance with GAAP and is susceptible to varying calculations, EBITDA, as presented, may not be comparable to other similarly titled measures of other companies. Revenues and expenses are measured in accordance with the policies and procedures described in the Company's Annual Report on Form 10-K for the year ended December 31, 2022.
FUSE MEDICAL, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in dollars, except share data)
| |
|
June 30,
|
|
|
December 31,
|
|
| |
|
2023
|
|
|
2022
|
|
| |
|
(Unaudited)
|
|
|
|
|
|
|
Assets
|
|
|
|
|
|
|
|
|
|
Current assets:
|
|
|
|
|
|
|
|
|
|
Cash
|
|
$ |
253,378 |
|
|
$ |
147,854 |
|
|
Accounts receivable, net of allowance of $200,798 and $290,500, respectively
|
|
|
3,433,900 |
|
|
|
3,996,860 |
|
|
Inventories, net of allowance of $1,521,421 and $1,778,173, respectively
|
|
|
9,026,923 |
|
|
|
9,494,506 |
|
|
Prepaid expenses and other current assets
|
|
|
104,363 |
|
|
|
126,022 |
|
|
Total current assets
|
|
|
12,818,564 |
|
|
|
13,765,242 |
|
|
Property and equipment, net
|
|
|
- |
|
|
|
709 |
|
|
Long term accounts receivable, net of allowance of $5,172,858 and $4,330,883, respectively
|
|
|
3,401,297 |
|
|
|
2,832,764 |
|
|
Intangible assets, net
|
|
|
1,125,549 |
|
|
|
1,190,980 |
|
|
Goodwill
|
|
|
1,972,886 |
|
|
|
1,972,886 |
|
|
Total assets
|
|
$ |
19,318,296 |
|
|
$ |
19,762,581 |
|
|
Liabilities and Stockholders' Equity (Accumulated Deficit)
|
|
|
|
|
|
|
|
|
|
Current liabilities:
|
|
|
|
|
|
|
|
|
|
Accounts payable
|
|
$ |
4,238,209 |
|
|
$ |
5,700,236 |
|
|
Accrued expenses
|
|
|
5,605,104 |
|
|
|
4,540,366 |
|
|
Notes payable - related parties
|
|
|
350,000 |
|
|
|
150,000 |
|
|
Senior secured revolving credit facility
|
|
|
1,870,912 |
|
|
|
1,997,135 |
|
|
Total current liabilities
|
|
|
12,064,225 |
|
|
|
12,387,737 |
|
|
Notes payable - related parties
|
|
|
- |
|
|
|
200,000 |
|
|
Earn-out liability
|
|
|
7,485,698 |
|
|
|
7,485,698 |
|
|
Total liabilities
|
|
|
19,549,923 |
|
|
|
20,073,435 |
|
|
Commitments and contingencies
|
|
|
- |
|
|
|
- |
|
|
Stockholders' equity (accumulated deficit)
|
|
|
|
|
|
|
|
|
|
Preferred stock, $0.01 par value; 20,000,000 shares authorized, no shares issued and outstanding
|
|
|
- |
|
|
|
- |
|
|
Common stock, $0.01 par value; 100,000,000 shares authorized, 73,895,794 shares issued and outstanding as of June 30, 2023 and December 31, 2022
|
|
|
738,958 |
|
|
|
738,958 |
|
|
Additional paid-in capital
|
|
|
1,468,274 |
|
|
|
1,468,274 |
|
|
Accumulated deficit
|
|
|
(2,438,859 |
)
|
|
|
(2,518,086 |
)
|
|
Total stockholders' equity (accumulated deficit)
|
|
|
(231,627 |
)
|
|
|
(310,854 |
)
|
|
Total liabilities and stockholders' equity (accumulated deficit)
|
|
$ |
19,318,296 |
|
|
$ |
19,762,581 |
|
FUSE MEDICAL, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
(in dollars, except share data)
| |
|
For the Three Months Ended June 30,
|
|
|
For the Six Months Ended June 30,
|
|
| |
|
2023
|
|
|
2022 Revised
|
|
|
2023
|
|
|
2022 Revised
|
|
|
Net revenues
|
|
$ |
4,997,212 |
|
|
$ |
4,668,290 |
|
|
$ |
8,981,667 |
|
|
$ |
9,222,628 |
|
|
Cost of revenues
|
|
|
1,528,321 |
|
|
|
2,028,497 |
|
|
|
2,696,723 |
|
|
|
3,771,806 |
|
|
Gross profit
|
|
|
3,468,891 |
|
|
|
2,639,793 |
|
|
|
6,284,944 |
|
|
|
5,450,822 |
|
|
Operating expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling, general, administrative and other
|
|
|
1,618,160 |
|
|
|
1,422,768 |
|
|
|
3,324,487 |
|
|
|
3,132,309 |
|
|
Commissions
|
|
|
1,449,157 |
|
|
|
1,463,859 |
|
|
|
2,691,034 |
|
|
|
2,969,530 |
|
|
Depreciation and amortization
|
|
|
32,715 |
|
|
|
34,404 |
|
|
|
66,140 |
|
|
|
68,806 |
|
|
Total operating expenses
|
|
|
3,100,032 |
|
|
|
2,921,031 |
|
|
|
6,081,661 |
|
|
|
6,170,645 |
|
|
Operating (loss) profit
|
|
|
368,859 |
|
|
|
(281,238 |
)
|
|
|
203,283 |
|
|
|
(719,823 |
)
|
|
Other (income) expense:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense
|
|
|
54,024 |
|
|
|
36,527 |
|
|
|
111,217 |
|
|
|
69,485 |
|
|
Total other (income) expense
|
|
|
54,024 |
|
|
|
36,527 |
|
|
|
111,217 |
|
|
|
69,485 |
|
|
Net income (loss) before income tax
|
|
|
314,835 |
|
|
|
(317,765 |
)
|
|
|
92,066 |
|
|
|
(789,308 |
)
|
|
Income tax expense
|
|
|
7,247 |
|
|
|
5,171 |
|
|
|
12,839 |
|
|
|
10,027 |
|
|
Net income (loss)
|
|
$ |
307,588 |
|
|
$ |
(322,936 |
)
|
|
$ |
79,227 |
|
|
$ |
(799,335 |
)
|
|
Net income (loss) per common share - basic and diluted
|
|
$ |
0.00 |
|
|
$ |
(0.00 |
)
|
|
$ |
0.00 |
|
|
$ |
(0.01 |
)
|
|
Weighted average number of common shares outstanding - basic
|
|
|
70,321,566 |
|
|
|
70,321,566 |
|
|
|
70,321,566 |
|
|
|
70,321,566 |
|
|
Weighted average number of common shares outstanding - diluted
|
|
|
75,976,582 |
|
|
|
70,321,566 |
|
|
|
75,976,582 |
|
|
|
70,321,566 |
|
|
Supplemental Non-GAAP Disclosure
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
EBITDA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
Three Months Ended June 30,
|
|
|
For the Six Months Ended June 30,
|
|
| |
|
2023
|
|
|
2022 Revised
|
|
|
2023
|
|
|
2022 Revised
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss)
|
|
$ |
307,588 |
|
|
$ |
(322,936 |
)
|
|
$ |
79,227 |
|
|
$ |
(799,335 |
)
|
|
Add (Deduct):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income tax expense (benefit)
|
|
|
7,247 |
|
|
|
5,171 |
|
|
|
12,839 |
|
|
|
10,027 |
|
|
Interest expense
|
|
|
54,024 |
|
|
|
36,527 |
|
|
|
111,217 |
|
|
|
69,485 |
|
|
Depreciation and amortization
|
|
|
32,715 |
|
|
|
14,493 |
|
|
|
66,140 |
|
|
|
68,806 |
|
|
EBITDA
|
|
$ |
401,574 |
|
|
$ |
(266,745 |
)
|
|
$ |
269,423 |
|
|
$ |
(651,017 |
)
|
FUSE MEDICAL, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
| |
|
For the Six Months Ended June 30,
|
|
| |
|
2023
|
|
|
2022 Revised
|
|
|
Cash flows from operating activities
|
|
|
|
|
|
|
|
|
|
Net income (loss)
|
|
$ |
79,227 |
|
|
$ |
(799,335 |
)
|
|
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
|
|
66,140 |
|
|
|
68,806 |
|
|
Stock based compensation
|
|
|
- |
|
|
|
16,946 |
|
|
Provision for bad debts and discounts
|
|
|
(89,703 |
)
|
|
|
(102,595 |
)
|
|
Provision for long term accounts receivable
|
|
|
841,975 |
|
|
|
402,200 |
|
|
Provision for slow moving inventory
|
|
|
(256,752 |
)
|
|
|
(94,595 |
)
|
|
Changes in operating assets and liabilities:
|
|
|
|
|
|
|
|
|
|
Accounts receivable
|
|
|
652,663 |
|
|
|
666,843 |
|
|
Inventories
|
|
|
724,335 |
|
|
|
(526,213 |
)
|
|
Prepaid expenses and other current assets
|
|
|
21,659 |
|
|
|
(89,410 |
)
|
|
Long term accounts receivable
|
|
|
(1,410,508 |
)
|
|
|
(670,332 |
)
|
|
Accounts payable
|
|
|
(1,462,027 |
)
|
|
|
320,071 |
|
|
Accrued expenses
|
|
|
1,064,738 |
|
|
|
1,055,519 |
|
|
Net cash provided by operating activities
|
|
|
231,747 |
|
|
|
247,905 |
|
| |
|
|
|
|
|
|
|
|
|
Cash flows from investing activities
|
|
|
|
|
|
|
|
|
|
Purchase of property and equipment
|
|
|
- |
|
|
|
- |
|
|
Net cash (used in) investing activities
|
|
|
- |
|
|
|
- |
|
| |
|
|
|
|
|
|
|
|
|
Cash flows from financing activities
|
|
|
|
|
|
|
|
|
|
Net payments on senior secured revolving credit facility
|
|
|
(126,223 |
)
|
|
|
(197,099 |
)
|
|
Net cash (used in) financing activities
|
|
|
(126,223 |
)
|
|
|
(197,099 |
)
|
| |
|
|
|
|
|
|
|
|
|
Net increase (decrease) in cash
|
|
|
105,524 |
|
|
|
50,806 |
|
|
Cash and cash equivalents - beginning of period
|
|
|
147,854 |
|
|
|
553,190 |
|
|
Cash and cash equivalents - end of period
|
|
$ |
253,378 |
|
|
$ |
603,996 |
|
|
Supplemental disclosure of cash flow information:
|
|
|
|
|
|
|
|
|
|
Cash paid for interest
|
|
$ |
92,833 |
|
|
$ |
50,796 |
|
v3.23.2
Document And Entity Information
|
Aug. 14, 2023 |
| Document Information [Line Items] |
|
| Entity, Registrant Name |
FUSE MEDICAL, INC.
|
| Document, Type |
8-K
|
| Document, Period End Date |
Aug. 14, 2023
|
| Entity, Incorporation, State or Country Code |
DE
|
| Entity, File Number |
000-10093
|
| Entity, Tax Identification Number |
59-1224913
|
| Entity, Address, Address Line One |
1565 North Central Expressway
|
| Entity, Address, Address Line Two |
Suite 220
|
| Entity, Address, City or Town |
Richardson
|
| Entity, Address, State or Province |
TX
|
| Entity, Address, Postal Zip Code |
75080
|
| City Area Code |
469
|
| Local Phone Number |
862-3030
|
| Written Communications |
false
|
| Soliciting Material |
false
|
| Pre-commencement Tender Offer |
false
|
| Pre-commencement Issuer Tender Offer |
false
|
| Title of 12(b) Security |
Common Stock
|
| Trading Symbol |
FZMD
|
| Entity, Emerging Growth Company |
false
|
| Amendment Flag |
false
|
| Entity, Central Index Key |
0000319016
|
| X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
| Name: |
dei_AmendmentFlag |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
| Name: |
dei_DocumentPeriodEndDate |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:dateItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
| Name: |
dei_DocumentType |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:submissionTypeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
| Name: |
dei_EntityAddressAddressLine1 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 2 such as Street or Suite number
| Name: |
dei_EntityAddressAddressLine2 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Definition
+ References
+ Details
| Name: |
dei_EntityAddressCityOrTown |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCode for the postal or zip code
| Name: |
dei_EntityAddressPostalZipCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the state or province.
| Name: |
dei_EntityAddressStateOrProvince |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:stateOrProvinceItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityCentralIndexKey |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:centralIndexKeyItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionIndicate if registrant meets the emerging growth company criteria. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityEmergingGrowthCompany |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
| Name: |
dei_EntityFileNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:fileNumberItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
| Name: |
dei_EntityIncorporationStateCountryCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarStateCountryItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityRegistrantName |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityTaxIdentificationNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:employerIdItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionLocal phone number for entity.
| Name: |
dei_LocalPhoneNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
| Name: |
dei_PreCommencementIssuerTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
| Name: |
dei_PreCommencementTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTitle of a 12(b) registered security. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
| Name: |
dei_Security12bTitle |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:securityTitleItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Section 14a
-Number 240
-Subsection 12
| Name: |
dei_SolicitingMaterial |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
| Name: |
dei_TradingSymbol |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:tradingSymbolItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
| Name: |
dei_WrittenCommunications |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
Fuse Medical (PK) (USOTC:FZMD)
Historical Stock Chart
From Nov 2024 to Dec 2024
Fuse Medical (PK) (USOTC:FZMD)
Historical Stock Chart
From Dec 2023 to Dec 2024
